intro image

Perform timely antifungal susceptibility testing with VITEK 2 AST-YS09 Ref 423331

Antifungal Resistance is a Public Health Challenge

"Candida is a leading cause of healthcare-associated bloodstream infections in U.S. hospitals. Each case of Candida bloodstream infection is estimated to result in an additional 3 to 13 days of hospitalization and $6,000 to $29,000 in healthcare costs. About 7% of all Candida bloodstream isolates tested at CDC are resistant to fluconazole and more than 70% of these resistant isolates are Candida glabrata or Candida krusei."1

In two studies of patients with Candida bloodstream infections, delays of 12-14 hours resulted in a mortality rate 2-3 times higher compared to patients who received more timely antifungal therapy.2,3

The IDSA Recommends Antifungal Susceptibility Testing for Bloodstream Infections4
The VITEK 2 AST-YS09 panel includes: caspofungin, fluconazole, flucytosine, micafungin, and voriconazole. This card provides an automated and standardized antifungal susceptibility testing platform.

AST-YS09 card (Ref. 423331) calling ranges:

Antifungal Agents Calling Range
Caspofungin 0.125 8
Fluconazole 0.5 64
Flucytosine 1 64
Micafungin 0.06 8
Voriconazole 0.12 8

Additional antifungal agents are available with ETEST®—a reliable and valuable manual MIC AST solution to guide therapy and manage treatment.

For more information, please fill out the Request More Information Form and a bioMérieux, Inc. representative will contact you.


1. Antifungal Resistance. Centers for Disease Control website Updated September 6, 2018. Accessed April 29, 2019.
2. Morgan J, Meltzer MI, Plikaytis BD, et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Inf Control Hosp Epidemiol. 2005;26:540-547. DOI: 10.1086/502581
3. Vallabhaneni S, Cleveland A, Farley M, et al. Epidemiology and risk factors for echinocandin nonsusceptible Candida glabrata bloodstreamiInfections: Data from a large multisite population-based candidemia surveillance program, 2008–2014. Open Forum Infect Dis. 2015;2(4):ofv163. DOI: 10.1093/ofid/ofv163
4. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-e50. DOI: 10.1093/cid/civ933